A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
. N Engl J Med 2004; 351: 2817-2826.
Sparano, M.D., from the Montefiore Medical Center in Bronx, N.Y., and colleagues randomized 69 percent of 9,719 eligible women with hormone-receptor-positive, HER2-negative, axillary node-negative breast cancer
with a midrange recurrence score of 11 to 25 to either chemoendocrine therapy or endocrine therapy alone.
Quantitative assessment of lymph vascular space invasion (LVSI) provides important prognostic information in node-negative breast cancer
. Ann Oncol 2013;24:2994-8.
Schmidt et al., "Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer
: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6xFEC versus 3xFEC/3xDocetaxel," BMC Cancer, vol.
10-yr follow-up results of NSABP B32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer
A multi gene assay to predict recurrence of tamoxifen-treated node-negative breast cancer
. N Engl J Med.
Fluorescence In Situ Hybridization and Immunohistochemical Assays for HER-2/neu Status Determination; Application to Node-Negative Breast Cancer
. Archives of Pathology & Laboratory Medicine: Vol.
Key clinical point: A 70-gene signature screen for chemotherapy guidance for node-negative breast cancer
patients did not lead to better outcomes compared with a free online tool or giving all patients chemotherapy.
The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer
. BMC cancer,;8(1): 307.
Patterns of initial management of node-negative breast cancer
in two Canadian provinces.
Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer
: results from the NSABP B-32 randomised phase III trial.
Recent publication of the survival analysis from the NSABP B-32 trial provides level- one evidence confirming findings from numerous retrospective cohort studies demonstrating the oncological equivalence of sentinel node biopsy (SNB) to axillary clearance in clinically node-negative breast cancer
, This and other studies including the ALMANAC Trial , have previously confirmed reduced morbidity and improved patient-reported outcomes with SNB.